23 July 2020 Analysis
The blood-brain barrier protects the brain from dangerous pathogens and toxins but is notoriously difficult to penetrate with medications. Chloe Kent finds out more about the difficulties of overcoming this...
14 July 2020 Analysis
VistaGen and EverInsight have signed a development and commercialisation agreement for the former’s first-in-class drug for social anxiety disorder. The deal focuses on the Greater China, South Korea and Southeast...
25 June 2020 News
US-based Yumanity Therapeutics has signed a research collaboration and licence agreement with Merck (MSD) to develop new therapies for neurodegenerative diseases.
11 March 2020 Comment
March is multiple sclerosis (MS) awareness month and this year the aim is to focus on the global awareness and understanding of the disease. Throughout the month, multiple sclerosis will...
6 March 2020 projects
Audentes Therapeutics, a genetic medicines company, is planning to build a gene therapy manufacturing facility in Sanford, North Carolina, US.
4 March 2020 Analysis
In 2019, the opioid crisis in the US reached its peak. It dominated the news and legislative agenda and two pharma companies declared bankruptcy as a result of multiple legal...
28 February 2020 News
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
25 February 2020 Comment
Epilepsy is a common neurological condition where abnormal activity in the brain leads to seizures. This condition is usually diagnosed after a person has experienced two or more unprovoked seizures....
11 February 2020 Company News
Eli Lilly has announced its drug solanezumab failed to meet its primary endpoint in the Phase II/III Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study.